Financial reports
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
28 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
13 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
VBI Vaccines Reports Full Year 2023 Financial Results
16 Apr 24
8-K
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11 Apr 24
8-K
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
3 Apr 24
8-K
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
2 Apr 24
8-K
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
14 Feb 24
8-K
Entry into a Material Definitive Agreement
6 Feb 24
8-K
Entry into a Material Definitive Agreement
23 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
8-K
Entry into a Material Definitive Agreement
26 Dec 23
8-K
Entry into a Material Definitive Agreement
12 Dec 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
11 Apr 24
424B5
Prospectus supplement for primary offering
7 Jul 23
424B5
Prospectus supplement for primary offering
7 Jul 23
424B5
Prospectus supplement for primary offering
5 Jul 23
D
$0 in equity / options / securities to be acquired, 1 investor
28 Sep 22
S-8
Registration of securities for employees
26 Aug 22
S-3
Shelf registration
26 Aug 22
424B5
Prospectus supplement for primary offering
3 Sep 21
S-8
Registration of securities for employees
3 Sep 21
S-8
Registration of securities for employees
31 Jul 20
Proxies
DEFA14A
Additional proxy soliciting materials
2 May 23
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
PRE 14A
Preliminary proxy
18 Apr 22
DEF 14A
Definitive proxy
26 Apr 21
DEFA14A
Additional proxy soliciting materials
26 Apr 21
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
Other
EFFECT
Notice of effectiveness
7 Sep 22
CORRESP
Correspondence with SEC
2 Sep 22
UPLOAD
Letter from SEC
2 Sep 22
CT ORDER
Confidential treatment order
11 Mar 19
EFFECT
Notice of effectiveness
30 Jul 18
CORRESP
Correspondence with SEC
26 Jul 18
UPLOAD
Letter from SEC
26 Jul 18
EFFECT
Notice of effectiveness
8 Jun 17
CORRESP
Correspondence with SEC
6 Jun 17
CORRESP
Correspondence with SEC
5 Jun 17
Ownership
SC 13D/A
PERCEPTIVE ADVISORS LLC
17 Apr 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
20 Nov 23
4
Michel DeWilde
31 Jul 23
4
Damian Braga
31 Jul 23
4
Jeff Baxter
28 Jul 23
4
Joanne Cordeiro
28 Jul 23
4
Nell Beattie
28 Jul 23
4
VAUGHN B HIMES
28 Jul 23
4
Avi Mazaltov
28 Jul 23
4
Francisco Diaz-Mitoma
28 Jul 23